-

Agilent to Webcast First-Quarter Fiscal Year 2021 Financial Results Presentation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release first-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, Feb. 16. The company will host a live webcast of its investor conference call in listen-only mode on the same day.

Details for the webcast:

Date: Tuesday, Feb. 16, 2021
Time: 1:30 p.m. Pacific time
Web access: Links will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website.

The webcast will remain on the company website for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Investor Contact:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent to issue first quarter fiscal year 2021 financial results Tuesday, Feb. 16.
Release Versions
$Cashtags

Contacts

Investor Contact:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom